• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Where next for gefitinib in patients with lung cancer?

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Blackhall, Fiona H
    Ranson, Malcolm R
    Thatcher, Nick
    Affiliation
    Cancer Research UK Department of Medical Oncology, Christie Hospital NHS Trust Manchester, M20 4BX, UK. Fiona.Blackhall@christie-tr.nwest.nhs.uk
    Issue Date
    2006-06
    
    Metadata
    Show full item record
    Abstract
    Gefitinib belongs to the small-molecule class of epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors. It was given conditional approval by the US Food and Drug Administration (FDA) in 2003 for treatment of advanced, chemorefractory non-small-cell lung cancer (NSCLC), but was relabelled for restricted use for patients that were already receiving and benefiting from it after the negative result of the phase III Iressa Survival Evaluation in Advanced Lung Cancer (ISEL) trial. By contrast, erlotinib, another EGFR tyrosine-kinase inhibitor, showed an overall survival benefit compared with placebo and best supportive care in the National Cancer Institute of Canada's BR21 trial, and now has full FDA approval for treatment of patients with NSCLC who have progressed after treatment with chemotherapy. Although the ISEL trial result was negative overall, preplanned subgroup analyses showed a significant overall survival benefit for gefitinib treatment in never-smokers and in patients of Asian origin. Here, we review the clinical experience with gefitinib and, in light of the licensing of erlotinib, address the lessons learned, the ongoing trials, and whether scope remains for clinical development of gefitinib in selected patients.
    Citation
    Where next for gefitinib in patients with lung cancer? 2006, 7 (6):499-507 Lancet Oncol.
    Journal
    The Lancet Oncology
    URI
    http://hdl.handle.net/10541/72519
    DOI
    10.1016/S1470-2045(06)70725-2
    PubMed ID
    16750500
    Type
    Article
    Language
    en
    ISSN
    1470-2045
    ae974a485f413a2113503eed53cd6c53
    10.1016/S1470-2045(06)70725-2
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
    • Authors: Oxnard GR, Miller VA
    • Issue date: 2010 Apr 30
    • Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
    • Authors: Stinchcombe TE, Socinski MA
    • Issue date: 2008 Sep
    • Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    • Authors: Patel JD, Pasche B, Argiris A
    • Issue date: 2004 Jun
    • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    • Authors: Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ
    • Issue date: 2012 Jan
    • Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
    • Authors: Siegel-Lakhai WS, Beijnen JH, Schellens JH
    • Issue date: 2005 Sep
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.